Pharco Pharmaceuticals

Pharco Pharmaceuticals is the mother company of Pharco group, founded by Dr. Hassan Abbas Helmy in 1983. operating in the pharmaceutical field for development, manufacturing, marketing, distributing and exporting of a comprehensive array of generics and branded generic drugs under the name of Pharco, along with a rising number of licensed pharmaceutical products. Pharco Corp. is the largest manufacturer of pharmaceuticals in the MENA region, focused on research, formulation, manufacturing and commercialization of pharmaceutical products. Today Pharco Corp. employs over 8,000 employees, and has over 650 Million packs produced in 2017 — ranking as the leader in the Egyptian pharmaceutical market. Pharco also exports to 53 countries around the world. Pharco works towards one goal is to provide highly effective and safe pharmaceutical products to patients at an affordable price.a

Related News

ADDITIVE ORTHOPAEDICS® ANNOUNCES ADDITIVE MANUFACTURING CAPABILITY WITH PATIENT SPECIFIC IMPLANT LOCKING TECHNOLOGY

Additive Orthopaedics, LLC | October 23, 2020

news image

Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, announces a novel breakthrough in orthopaedic additive manufacturing with their ability to incorporate locking technology in all of their Patient Specific Implants. The patent pending technology can be incorporated in Additive Orthopaedics Patient Specific 3D Printed Plates and Patient Specific 3D Printed Bone Segments. According to Luciano Bertolotti, Director of Engineering for Additive Orthopaedics, &quo...

Read More

ALLIANCE FOR REGENERATIVE MEDICINE PUBLISHED ITS RESPONSE TO EU PHARMACEUTICAL ROADMAP

Alliance for Regenerative Medicine | July 07, 2020

news image

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organisation dedicated to realising the promise of regenerative medicines and advanced therapies, today published its response to the EU Pharmaceutical Strategy Roadmap which is designed to improve and accelerate patients’ access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry. The full response can be found on the European Commission website. While A...

Read More

PHARMA TECH

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Pfizer | December 21, 2020

news image

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More

BUSINESS INSIGHTS

GOODRX CLOSES ACQUISITION OF VITACARE, A TECH-ENABLED PHARMACY SERVICES PLATFORM

GoodRx | April 18, 2022

news image

GoodRx, a leading consumer-focused digital healthcare platform announced the completion of its previously announced acquisition of vitaCare for $150 million in cash, with an additional $7 million of consideration contingent payment upon vitaCare’s financial performance through 2023. VitaCare is a pharmacy services platform that expands GoodRx’s offering to pharmaceutical manufacturers while helping to improve patient access and adherence to affordable brand drugs. The acquisition wil...

Read More
news image

ADDITIVE ORTHOPAEDICS® ANNOUNCES ADDITIVE MANUFACTURING CAPABILITY WITH PATIENT SPECIFIC IMPLANT LOCKING TECHNOLOGY

Additive Orthopaedics, LLC | October 23, 2020

Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, announces a novel breakthrough in orthopaedic additive manufacturing with their ability to incorporate locking technology in all of their Patient Specific Implants. The patent pending technology can be incorporated in Additive Orthopaedics Patient Specific 3D Printed Plates and Patient Specific 3D Printed Bone Segments. According to Luciano Bertolotti, Director of Engineering for Additive Orthopaedics, &quo...

Read More
news image

ALLIANCE FOR REGENERATIVE MEDICINE PUBLISHED ITS RESPONSE TO EU PHARMACEUTICAL ROADMAP

Alliance for Regenerative Medicine | July 07, 2020

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organisation dedicated to realising the promise of regenerative medicines and advanced therapies, today published its response to the EU Pharmaceutical Strategy Roadmap which is designed to improve and accelerate patients’ access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry. The full response can be found on the European Commission website. While A...

Read More
news image

PHARMA TECH

FEDS REBUFF PFIZER'S PLEAS TO SPEED UP SUPPLIES OF COVID-19 VACCINE RAW MATERIALS

Pfizer | December 21, 2020

Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization. In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market? Pfizer could give more than the 100 million portions it guaranteed in it...

Read More
news image

BUSINESS INSIGHTS

GOODRX CLOSES ACQUISITION OF VITACARE, A TECH-ENABLED PHARMACY SERVICES PLATFORM

GoodRx | April 18, 2022

GoodRx, a leading consumer-focused digital healthcare platform announced the completion of its previously announced acquisition of vitaCare for $150 million in cash, with an additional $7 million of consideration contingent payment upon vitaCare’s financial performance through 2023. VitaCare is a pharmacy services platform that expands GoodRx’s offering to pharmaceutical manufacturers while helping to improve patient access and adherence to affordable brand drugs. The acquisition wil...

Read More